AstraZeneca Inks Upto$1.5B Licensing Deal With Allergan for MEDI2070

Allergan said today it has acquired global rights to AstraZeneca’s midstage inflammatory disorder candidate MEDI2070 through a licensing deal that could generate up to $1.52 billionplus for AstraZeneca.The agreement adds to Allergan’s p...